🇺🇸 FDA
Pipeline program

Shenlingcao Oral Liquid

20181009

Approved small_molecule completed

Quick answer

Shenlingcao Oral Liquid for Carcinoma, Non-Small-Cell Lung is a Approved program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Carcinoma, Non-Small-Cell Lung
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials